BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-255@pharmaconomics
DTSTAMP:20260707T015304Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:JAZZ Phase 3 — zanidatamab (estimated date)
DESCRIPTION:Phase 3 trial results for zanidatamab in HER2+ 1L gastroesophageal adenocarcinoma are due ~ Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1232524/000119312526009899/d61589dex991.htm\n\nTrack it: https://pharmaconomics.com/e/255
URL:https://pharmaconomics.com/e/255
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:JAZZ catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR